Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jgh3.70322 http://scihub22266oqcxt.onion/10.1002/jgh3.70322 C12689938!12689938 !41384275     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41384275 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       JGH+Open 2025 ; 9 (12 ): e70322 Nephropedia Template TP {{tp|p=41384275 |t=2025. Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn s Disease: Results of the AURORA Study, Including the ANZIBD Consortium |pdf=|usr=}}{{41384275 }} gab.com Text Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn s Disease: Results of the AURORA Study, Including the ANZIBD Consortium JO: JGH Open http://www.kidney.de/pget.php?&tw=1&pmid=41384275 #FOAvip BACKGROUND: Ustekinumab is an effective therapy for the management of Crohn's disease. Australia is unique, as ustekinumab can be prescribed as first-line biologic therapy, and there is high concomitant immunomodulator use. AIM: To evaluate the real-world efficacy and safety of ustekinumab in moderate to severe Crohn's disease. METHODS: A multicentre prospective cohort study was conducted at 19 Australian centres between September 2019 and April 2022. Clinical assessments were performed at baseline, 3, 9 and 15?months. Logistic regression analyses were performed to identify predictors of clinical response and remission. RESULTS: 197 patients (male 45.2%) were included: 58.9% were biologic-naïve and 50.0% were on concomitant immunomodulators. Clinical response rates were 75.4%, 75.5% and 72.3% at 3, 9 and 15?months, respectively with corresponding clinical remission rates of 45.8%, 51.6% and 55.5%. Clinical response and remission rates at 3 and 9?months were significantly higher in bio-naïve patients compared with biologic-exposed (p?<?0.01); but no significant differences were seen with concomitant immunomodulator use. Dose escalation was required in 31.5% of patients. Ustekinumab was discontinued in 12.7% of patients. The cumulative probability of maintaining ustekinumab treatment at 15?months was 84.4%. Despite 161 adverse events reported, including 41 hospitalizations, only eight patients required treatment discontinuation due to adverse events. CONCLUSIONS: This real-world study on the use of ustekinumab in Crohn's disease showed that short-term clinical response and remission rates are higher in bio-naïve compared with bio-exposed patients, with a high persistence rate at 15?months. The addition of an immunomodulator did not significantly impact outcomes. Ustekinumab was found to be safe in most patients. Twit Text FOAVip Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn s Disease: Results of the AURORA Study, Including the ANZIBD Consortium ????JGH Open http://www.kidney.de/pget.php?&tw=1&pmid=41384275 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41384275 #FOAvip English Wikipedia <ref>{{Cite pmid|41384275 }}</ref> Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn s Disease: Results of the AURORA Study, Including the ANZIBD Consortium #MMPMID41384275 An YK ; Lindsay N ; Allan N ; Khoo E ; Fernandes R ; Gilmore R ; Amiss A ; Pham H ; Ooi SY ; Thin L ; Lightowler D ; Connor SJ ; Williams A ; De Cruz P ; Li Wai Suen CFD ; Kariyawasam V ; Mitrev N ; Ghaly S ; Andrews JM ; Christensen B ; Sparrow MP ; White LS ; Bryant R ; Ding NS ; Leong RW ; Van Langenberg DR ; Seltenreich H ; Subramaniam K ; Radford-Smith G ; Begun J JGH Open 2025[Dec]; 9 (12 ): e70322 PMID41384275 show ga BACKGROUND: Ustekinumab is an effective therapy for the management of Crohn's disease. Australia is unique, as ustekinumab can be prescribed as first-line biologic therapy, and there is high concomitant immunomodulator use. AIM: To evaluate the real-world efficacy and safety of ustekinumab in moderate to severe Crohn's disease. METHODS: A multicentre prospective cohort study was conducted at 19 Australian centres between September 2019 and April 2022. Clinical assessments were performed at baseline, 3, 9 and 15?months. Logistic regression analyses were performed to identify predictors of clinical response and remission. RESULTS: 197 patients (male 45.2%) were included: 58.9% were biologic-naïve and 50.0% were on concomitant immunomodulators. Clinical response rates were 75.4%, 75.5% and 72.3% at 3, 9 and 15?months, respectively with corresponding clinical remission rates of 45.8%, 51.6% and 55.5%. Clinical response and remission rates at 3 and 9?months were significantly higher in bio-naïve patients compared with biologic-exposed (p? ?Australian Real-World Effectiveness and Safety of Ustekinumab for the (epmc).pdf DeepDyve Pubget Overpricing